Cary, N.C. , Oct. 1, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Eli Lilly and Company as a limited specialty pharmacy provider for Inluriyo™ (imlunestrant). This newly FDA-approved oral estrogen receptor antagonist is indicated for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
ESR1 mutations are found in approximately 50% of patients with ER+, HER2– metastatic breast cancer who have received hormone therapy and are known to contribute to treatment resistance. Inluriyo offers a once-daily oral option that binds, blocks and facilitates degradation of estrogen receptors, helping to slow disease progression.
“For individuals living with ER+, HER2–, ESR1-mutated advanced or metastatic breast cancer, Inluriyo offers a meaningful and convenient oral treatment option in a landscape where resistance to prior endocrine therapies is both common and challenging,” said Ela Lourido, vice president and general manager, Biologics by McKesson. “We are proud to be selected by Eli Lilly and Company as a specialty pharmacy provider for this important therapy and remain committed to supporting access and delivering compassionate, high-touch care to patients and providers.”
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For the full prescribing information for Inluriyo, please click here. For more information about the treatment of patients with ER+, HER2–, ESR1-mutated advanced or metastatic breast cancer, please visit Inluriyo.Lilly.com.